TRASTUZUMAB
Pyrotinib
First Affiliated Hospital of Zhejiang Universitymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Pyrotinib cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin First Affiliated Hospital of Zhejiang University | Phase 2 | CCC |
Vinorelbine Sun Yat-sen University | Phase 2 | CCC |
Pyrotinib Tianjin Medical University Cancer Institute and Hospital | Phase 2 | CCC |
Same molecule, other indications
TRASTUZUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →